{"id":"NCT00800683","sponsor":"Boehringer Ingelheim","briefTitle":"Safety and Efficacy in Type 2 Diabetic Patients With Severe Chronic Renal Impairment, 5 mg BI 1356 (Linagliptin) vs. Placebo, Insulin Background Inclusive","officialTitle":"Safety in Type 2 Diabetic Patients With Severe Chronic Renal Impairment, 5 mg BI 1356 vs. Placebo, DB, Parallel Group, Randomized, Insulin Background Inclusive","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-12","primaryCompletion":"2011-01","completion":null,"firstPosted":"2008-12-02","resultsPosted":"2012-02-01","lastUpdate":"2014-05-20"},"enrollment":133,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes Mellitus, Type 2"],"interventions":[{"type":"DRUG","name":"BI 1356","otherNames":[]},{"type":"DRUG","name":"placebo","otherNames":[]}],"arms":[{"label":"BI 1356","type":"EXPERIMENTAL"},{"label":"placebo","type":"PLACEBO_COMPARATOR"}],"summary":"to determine safety, efficacy and tolerability of BI 1356 versus placebo","primaryOutcome":{"measure":"HbA1c Change From Baseline at Week 12","timeFrame":"Baseline and Week 12","effectByArm":[{"arm":"Placebo","deltaMin":-0.15,"sd":0.15},{"arm":"Linagliptin (BI 1356)","deltaMin":-0.76,"sd":0.14}],"pValues":[{"comp":"OG000 vs OG001","p":"< 0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":3},"locations":{"siteCount":53,"countries":["United States","Australia","Hong Kong","Israel","New Zealand","Ukraine"]},"refs":{"pmids":["24169807"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":27,"n":65},"commonTop":["Hypoglycaemia","Hyperglycaemia","Hyperkalaemia","Diarrhoea","Oedema peripheral"]}}